Acta Haematologica
Brief Communication
Erythropoietin and Cyclophosphamide Combination Treatment Additively Enhances Antibody Production in MiceLifshitz L.a · Berger A.a · Mittelman M.b · Neumann D.aaDepartment of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, bDepartment of Medicine, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
|
|
Acta Haematol 2010;123:81–83
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Received: August 18, 2009
Accepted: October 12, 2009
Published online: December 23, 2009
Issue release date: February 2010
Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0
ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)
For additional information: https://www.karger.com/AHA
First-Page Preview
Related Articles:
References
- Cheer SM, Wagstaff AJ: Epoetin beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 2004;64:323–346.
- Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14–31.
- Longmore GD: Do cancer cells express functional erythropoietin receptors? N Engl J Med 2007;356:2447.
- Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;67:39–61.
- Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A: Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol 1997;98:204–210.
- Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181–5186.
- Prutchi-Sagiv S, Golishevsky N, Oster HS, Katz O, Cohen A, Naparstek E, Neumann D, Mittelman M: Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol 2006;135:660–672.
- Katz O, Gil L, Lifshitz L, Prutchi-Sagiv S, Gassmann M, Mittelman M, Neumann D: Erythropoietin enhances immune responses in mice. Eur J Immunol 2007;37:1584–1593.
- Turk JL, Parker D: Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev 1982;65:99–113.
- Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862–2868.
- Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D: Non-erythroid activities of erythropoietin: functional effects on murine dendritic cells. Mol Immunol 2009;46:713–721.
- Prutchi Sagiv S, Lifshitz L, Orkin R, Mittelman M, Neumann D: Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator? Exp Hematol 2008;36:1682–1690.
Article / Publication Details
Received: August 18, 2009
Accepted: October 12, 2009
Published online: December 23, 2009
Issue release date: February 2010
Number of Print Pages: 3
Number of Figures: 1
Number of Tables: 0
ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)
For additional information: https://www.karger.com/AHA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
